Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week

Eur Heart J. 2022 Oct 7;43(37):3512-3527. doi: 10.1093/eurheartj/ehac294.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / drug therapy
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use
  • Stents

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors